52 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Quantized surface complementarity diversity (QSCD): a model based on small molecule-target complementarity.
Neogenesis
Structure-activity relationships of (E)-3-(1,4-benzoquinonyl)-2-[(3-pyridyl)-alkyl]-2-propenoic acid derivatives that inhibit both 5-lipoxygenase and thromboxane A2 synthetase.
Eisai
Novel dual inhibitors of 5-lipoxygenase and thromboxane A2 synthetase: synthesis and structure-activity relationships of 3-pyridylmethyl-substituted 2-amino-6-hydroxybenzothiazole derivatives.
Eisai
Synthesis of structural analogs of leukotriene B4 and their receptor binding activity.
Smithkline Beecham Pharmaceuticals
Synthesis and pharmacologic activity of hydroxyacetophenone-substituted benzophenone/xanthone leukotriene B4 receptor antagonists
TBA
Discovery of novel and potent leukotriene B4 receptor antagonists. Part 1.
Roche Research Center
New Leukotriene B4 Receptor Antagonist: Leucettamine A and Related Imidazole Alkaloids from the Marine Sponge Leucetta microraphis
TBA
N-aryl cinnamides: A novel class of rigid and highly potent leukotriene B4 receptor antagonists
TBA
3-Amino-1,2-benzisoxazoles: A new family of potent inhibitors of LTB4 binding to the human neutrophils
TBA
Synthesis and pharmacological profile of new 1,3-disubstituted cyclohexanes as leukotriene B4 receptor antagonists
TBA
Synthesis and in vitro profile of 7-substituted quinoline chromanols as novel, non-acidic LTB4 antagonists
TBA
2-alkyl-4-ethyl-5-[6-methyl-6-(2H-tetrazol-5-yl)heptyloxy]phenol leukotriene B4 receptor antagonists
TBA
Synthesis and pharmacological activity of SC-53228, a leukotriene B4 receptor antagonist with high intrinsic potency and selectivity
TBA
Structural analogues of LY292728, a highly potent xanthone dicarboxylic acid leukotriene B4 receptor antagonist: spatial positioning of the secondary acid group
TBA
Acid unit modifications of 1,2,4,5-substituted hydroxyacetophenones and the effect on in vitro and in vivo LTB4 receptor antagonism
TBA
Enantioselective total synthesis and pharmacologic profile of 12-deoxy-12(S)-methyl leukotriene B4
TBA
Synthesis of leukotriene B4 antagonists labeled with In-111 or Tc-99m to image infectious and inflammatory foci.
Bristol-Myers Squibb Medical Imaging
Structure-activity relationships of indole cytosolic phospholipase A(2)alpha inhibitors: substrate mimetics.
Wyeth Research
Leukotriene B4 photoaffinity probes: design, synthesis and evaluation of new arylazide-1,3-disubstituted cyclohexanes.
Upresa-Cnrs 5074
Human disorders associated with inflammation and the evolving role of natural products to overcome.
University of Delhi
Carboxy-substituted cinnamides: a novel series of potent, orally active LTB4 receptor antagonists.
Novartis Pharmaceuticals
(E)-3-[6-[[(2,6-dichlorophenyl)thio]methyl]-3-(2-phenylethoxy)-2- pyridinyl]-2-propenoic acid: a high-affinity leukotriene B4 receptor antagonist with oral antiinflammatory activity.
Smithkline Beecham Pharmaceuticals
Structure-activity relationships study of two series of leukotriene B4 antagonists: novel indolyl and naphthyl compounds substituted with a 2-[methyl(2-phenethyl)amino]-2-oxoethyl side chain.
RhôNe-Poulenc Rorer
A novel series of [2-[methyl(2-phenethyl)amino]-2-oxoethyl] benzene-containing leukotriene B4 antagonists: initial structure-activity relationships.
Rhone-Poulenc Rorer Central Research
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid: a novel high-affinity leukotriene B4 receptor antagonist.
Smithkline Beecham Pharmaceuticals
Design, synthesis, and pharmacological evaluation of potent xanthone dicarboxylic acid leukotriene B4 receptor antagonists.
Eli Lilly
Biphenylyl-substituted xanthones: highly potent leukotriene B4 receptor antagonists.
Eli Lilly
Development of high-affinity 5-HT3 receptor antagonists. Structure-affinity relationships of novel 1,7-annelated indole derivatives.
Solvay Duphar
Synthesis and LTB4 receptor antagonist activities of the naturally occurring LTB4 receptor antagonist Leucettamine A and related analogues.
Smithkline Beecham Pharmaceuticals
Trisubstituted pyridine leukotriene B4 receptor antagonists: synthesis and structure-activity relationships.
Smithkline Beecham Pharmaceuticals
Leukotriene B4 (LTB4) receptor antagonists: a series of (hydroxyphenyl)pyrazoles.
Eli Lilly
(E)-3-[[[[6-(2-carboxyethenyl)-5-[[8-(4- methoxyphenyl)octyl]oxy]-2-pyridinyl]-methyl]thio]methyl]benzoic acid and related compounds: high affinity leukotriene B4 receptor antagonists.
Smithkline Beecham Pharmaceuticals
(+)-1-(3S,4R)-[3-(4-phenylbenzyl)-4-hydroxychroman-7-yl]cyclopentane carboxylic acid, a highly potent, selective leukotriene B4 antagonist with oral activity in the murine collagen-induced arthritis model.
Pfizer
Second-generation leukotriene B4 receptor antagonists related to SC-41930: heterocyclic replacement of the methyl ketone pharmacophore.
Searle Research and Development
Synthetic and structure/activity studies on acid-substituted 2-arylphenols: discovery of 2-[2-propyl-3-[3-[2-ethyl-4-(4-fluorophenyl)-5- hydroxyphenoxy]-propoxy]phenoxy]benzoic acid, a high-affinity leukotriene B4 receptor antagonist.
Eli Lilly
Bis(sulfato)-cyclosiphonodictyol A, a new disulfated sesquiterpene-hydroquinone from a deep water collection of the Marine sponge Siphonodictyon coralliphagum.
Harbor Branch Oceanographic Institution
7-[3-(4-acetyl-3-methoxy-2-propylphenoxy)propoxy]-3,4-dihydro-8- propyl-2H-1-benzopyran-2-carboxylic acid: an orally active selective leukotriene B4 receptor antagonist.
G.D. Searle And
Benzophenone dicarboxylic acid antagonists of leukotriene B4. 2. Structure-activity relationships of the lipophilic side chain.
Eli Lilly
omega-[(4,6-Diphenyl-2-pyridyl)oxy]alkanoic acid derivatives: a new family of potent and orally active LTB4 antagonists.
Centre De Recherche De Vitry-Alfortville
omega-[(4-Phenyl-2-quinolyl)oxy]alkanoic acid derivatives: a new family of potent LTB4 antagonists.
Centre De Recherche De Vitry-Alfortville
4-[2-[Methyl(2-phenethyl)amino]-2-oxoethyl]-8-(phenylmethoxy)-2- naphthalenecarboxylic acid: a high affinity, competitive, orally active leukotriene B4 receptor antagonist.
Rhone-Poulenc Rorer Central Research
Omega-[(omega-arylalkyl)thienyl]alkanoic acids: from specific LTA4 hydrolase inhibitors to LTB4 receptor antagonists.
Centre De Recherche De Vitry-Alfortville
Development of 2,3-dihydro-6-(3-phenoxypropyl)-2-(2-phenylethyl)-5-benzofuranol (L-670,630) as a potent and orally active inhibitor of 5-lipoxygenase.
Merck Frosst Centre For Therapeutic Research
Sulfonamide compounds and uses as TNAP inhibitors
Sanford-Burnham Prebys Medical Discovery Institute
Substituted pyrimidine-5-carboxamides as spleen tyrosine kinase inhibitors
Ziarco Pharma